Lamivudine
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | EPIVIR-HBV | — | 2001-08-16 – 2018-11-15 | fda.gov ↗ |
| Label expansions (6) | US (FDA) | EPIVIR | — | 1997-04-11 – 2016-07-20 | fda.gov ↗ |
| Approved | EU (EMA) | Epivir | — | 1996-08-08 | europa.eu ↗ |
| Approved | US (FDA) | EPIVIR | — | 1995-11-17 | fda.gov ↗ |
Trials 336 · started per year
Also used as a comparator or background therapy in 268 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00719602 Comparator | Aug 2009 → Aug 2013 | HIV infectious disease, malaria | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | Completed | No outcome recorded |
| Phase 116 trials | ||||||
| Phase 1 | NCT07115368 Background | Aug → Sep 2025 | HIV infectious disease | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1 | NCT07001319 Background | May 2025 → Mar 2026 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT06428045 Background | Apr 2025 → Apr 2029 expected | malignant glioma | University of Miami | Recruiting | No outcome recorded |
| Phase 1 | NCT05585307 Background | Oct 2022 → Feb 2024 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT04283656 Background | Jan → Oct 2022 | HIV infectious disease | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1 | NCT04424264 Background | Dec 2019 → Oct 2020 | HIV infectious disease, tuberculosis | Professor Francois Venter | Completed | No outcome recorded |
| Phase 1 | NCT02832778 Background | Nov 2016 → Jan 2018 | HIV infectious disease | St Stephens Aids Trust | Unknown | No outcome recorded |
| Phase 1 | NCT02556268 Background | Feb → Dec 2016 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02499874 Background | Aug 2015 → Oct 2017 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 1 | NCT01353742 Comparator | Feb → Apr 2011 | chronic hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00326716 Background | Jun 2006 → Jan 2009 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00000887 Background | ? → Jul 2004 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00000834 Background | ? → Jun 2002 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00000952 Background | ? → Jan 2004 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00000901 Background | ? → Oct 2000 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00000899 Background | ? → Oct 2001 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT03435146 Background | Jan 2018 → Dec 2022 | HIV infectious disease, respiratory tract infectious disorder | The Aurum Institute NPC | Completed | No outcome recorded |
| Phase 1/2 | NCT01844063 Background | Jul 2013 → Jan 2016 | liver failure | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01718587 Comparator | Nov 2012 → May 2013 | cirrhosis of liver | General Hospital of Chinese Armed Police Forces | Unknown | No outcome recorded |
| Phase 1/2 | NCT00985647 Comparator | Dec 2009 → Feb 2010 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00312039 Comparator | Mar 2006 → Oct 2007 | HIV infectious disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00004578 Comparator | Nov 1997 → Apr 2005 | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 247 trials | ||||||
| Phase 2 | NCT07202546 Comparator | Feb 2026 → Jul 2027 expected | HIV infectious disease | ViiV Healthcare | Recruiting | No outcome recorded |
| Phase 2 | NCT06774872 Background | Apr 2025 → Jan 2027 expected | HIV infectious disease | Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida | Recruiting | No outcome recorded |
| Phase 2 | NCT06799650 Background | Jan → Nov 2025 overdue | post-viral disorder | Federal University of São Paulo | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05630872 Background | Feb 2024 → May 2025 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT06061536 Background | Nov 2023 → Nov 2024 | HIV infectious disease | Shanxi Kangbao Biological Product Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06676410 Comparator | Jul 2023 → Dec 2024 overdue | HIV infectious disease | Code Pharma | Recruiting | No outcome recorded |
| Phase 2 | NCT05729568 Background | May 2023 → Jul 2024 overdue | HIV infectious disease | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04731103 Comparator | Aug 2022 → Mar 2024 | Aicardi-Goutieres syndrome | University of Edinburgh | Completed | No outcome recorded |
| Phase 2 | NCT04900038 Comparator | Aug 2021 → Nov 2022 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded |
| Phase 2 | NCT04871113 Background | Jun 2021 → Oct 2022 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT04012931 Background | Jul 2019 → Feb 2023 | HIV infectious disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03602690 Background | Oct 2018 → Apr 2022 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Unknown | No outcome recorded |
| Phase 2 | NCT03491553 Background | Apr 2018 → Mar 2019 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT03272347 Background | Nov 2017 → Mar 2021 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT02862548 Comparator | Sep 2016 → Feb 2018 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02750059 Comparator | Jan 2015 → Feb 2018 | — | SEARCH Research Foundation | Completed | No outcome recorded |
| Phase 2 | NCT01943799 Background | Sep 2013 → Sep 2014 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01706575 Background | Jan → Sep 2013 | chronic hepatitis B virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01641809 Background | Aug 2012 → Oct 2013 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT01125696 Comparator | May 2012 → May 2018 | HIV infectious disease, hepatitis B virus infection | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2 | NCT01489046 Background | Feb 2011 → Mar 2013 | HIV infectious disease | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2 | NCT00799864 Background | Jan 2011 → Aug 2022 | — | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 2 | NCT00651066 Background | Jun 2010 → Sep 2012 | HIV infectious disease, tuberculosis | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 2 | NCT00822315 Background | Jul 2009 → Nov 2011 | HIV infectious disease, tuberculosis | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 2 | NCT00943540 Background | Jul 2009 → Dec 2010 | HIV infectious disease | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00915655 Background | Jul 2009 → Sep 2010 | HIV infectious disease | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 2 | NCT00640887 Background | Feb 2009 → Oct 2010 | HIV infectious disease, tuberculosis | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 2 | NCT01174914 Comparator | Mar 2008 → Mar 2010 | — | The Ojai Foundation | Completed | No outcome recorded |
| Phase 2 | NCT00380159 Background | Sep 2006 → Dec 2008 | HIV infectious disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00350272 Comparator | May 2006 → Aug 2007 | HIV infectious disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00126880 Comparator | Jul 2005 → Jan 2008 | HIV infectious disease | Avexa | Completed | No outcome recorded |
| Phase 2 | NCT00110305 Background | Jun 2005 → Dec 2011 | HIV infectious disease | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 2 | NCT00104429 Background | Jan 2005 → Jan 2006 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded |
| Phase 2 | NCT00100048 Background | Jan 2005 → Oct 2006 | AIDS | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00084149 Background | Feb 2004 → Jan 2008 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00075231 Background | Dec 2003 → ? | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00273975 Background | Jan 2002 → Dec 2004 | HIV infectious disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT01438424 Background | Jan 2001 → Dec 2009 | hepatitis B virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00004998 Background | Nov 1999 → ? | HIV infectious disease | Agouron Pharmaceuticals | Suspended | No outcome recorded |
| Phase 2 | NCT00004999 Background | Aug 1999 → ? | HIV infectious disease | Agouron Pharmaceuticals | Suspended | No outcome recorded |
| Phase 2 | NCT00002423 Background | Mar 1999 → ? | HIV infectious disease | Glaxo Wellcome | Completed | No outcome recorded |
| Phase 2 | NCT02249130 Background | Mar 1999 → Apr 2000 | HIV infectious disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00002162 Background | — | HIV infectious disease | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00001087 Background | ? → Jul 2000 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00002424 Background | — | HIV infectious disease | Merck Sharp & Dohme LLC | Suspended | No outcome recorded |
| Phase 2 | NCT00031070 Background | ? → Dec 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00000870 Background | ? → Mar 2007 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/310 trials | ||||||
| Phase 2/3 | NCT01837277 Background | Dec 2017 → Jul 2021 | immunodeficiency disease | Fundação Bahiana de Infectologia | Completed | No outcome recorded |
| Phase 2/3 | NCT02245022 Comparator | Mar 2017 → Dec 2018 | HIV infectious disease, pregnancy disorder | University of Liverpool | Completed | No outcome recorded |
| Phase 2/3 | NCT02016924 Background | Jan 2014 → Jun 2025 overdue | AIDS | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01127204 Comparator | Jun 2011 → Apr 2015 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 2/3 | NCT01210287 Comparator | Oct 2010 → Aug 2014 | lymphoma | Fudan University | Unknown | No outcome recorded |
| Phase 2/3 | NCT00612898 Comparator | Feb 2008 → Jan 2010 | HIV infectious disease | Avexa | Terminated | No outcome recorded |
| Phase 2/3 | NCT00495326 Comparator | Dec 2007 → Apr 2011 | AIDS, tuberculosis | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 2/3 | NCT00834457 Comparator | Jun 2007 → Jul 2009 | Kaposi's sarcoma | Parirenyatwa Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT00424814 Comparator | Mar 2007 → Sep 2011 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 2/3 | NCT00272480 Comparator | Nov 1999 → Jul 2002 | tropical spastic paraparesis | Imperial College London | Completed | No outcome recorded |
| Phase 383 trials | ||||||
| Phase 3 | NCT06203132 Background | Jan 2025 → Nov 2026 expected | HIV infectious disease | ANRS, Emerging Infectious Diseases | Recruiting | No outcome recorded |
| Phase 3 | NCT06630299 Comparator | Oct 2024 → Apr 2026 overdue | HIV infectious disease | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06138600 Comparator | Nov 2023 → Oct 2025 | HIV infectious disease | University of Witwatersrand, South Africa | Unknown | No outcome recorded |
| Phase 3 | NCT05154747 Comparator | Jun 2023 → Mar 2025 | HIV infectious disease | University College, London | Unknown | No outcome recorded |
| Phase 3 | NCT05457530 Comparator | Aug 2022 → May 2023 | HIV infectious disease, abdominal obesity-metabolic syndrome, obesity disorder | Prism Health North Texas | Withdrawn | No outcome recorded |
| Phase 3 | NCT04704024 Comparator | Sep 2021 → May 2026 overdue | hepatitis B virus infection | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04022967 Background | Sep 2020 → Feb 2025 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Unknown | No outcome recorded |
| Phase 3 | NCT04303598 Comparator | Apr 2020 → May 2022 | HIV infectious disease | Henan Genuine Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04155554 Comparator | Jan → Aug 2020 | HIV infectious disease | University Hospital of Siena | Unknown | No outcome recorded |
| Phase 3 | NCT03988452 Background | Jul 2019 → Sep 2020 | HIV infectious disease | Makerere University | Unknown | No outcome recorded |
| Phase 3 | NCT03595709 Background | Dec 2018 → Mar 2019 | HIV infectious disease | Yu-Jay Corp. | Completed | No outcome recorded |
| Phase 3 | NCT03563742 Background | Sep 2018 → Jun 2021 | HIV infectious disease | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 3 | NCT03631732 Comparator | Aug 2018 → Aug 2019 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT03256422 Background | Sep 2017 → Aug 2019 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT02938520 Comparator | Oct 2016 → Aug 2018 overdue | HIV infectious disease | ViiV Healthcare | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02777229 Background | Jul 2016 → Jul 2018 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT02596334 Comparator | Dec 2015 → Jun 2017 | HIV infectious disease | Centre Hospitalier Régional d'Orléans | Terminated | No outcome recorded |
| Phase 3 | NCT02616783 Comparator | Dec 2015 → Feb 2018 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02603107 Background | Nov 2015 → May 2017 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02273765 Background | Sep 2015 → Nov 2018 | HIV infectious disease, tuberculosis | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT03236584 Comparator | Sep 2015 → Mar 2018 | — | Uijeongbu St. Mary Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02469246 Comparator | Jun 2015 → Dec 2017 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02227238 Background | Dec 2014 → Aug 2017 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT02275780 Background | Dec 2014 → Sep 2016 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT03178084 Background | Oct 2014 → Nov 2016 | HIV infectious disease | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Completed | No outcome recorded |
| Phase 3 | NCT02219672 Comparator | Jul 2014 → Jul 2016 | AIDS | Peking Union Medical College | Unknown | No outcome recorded |
| Phase 3 | NCT02157311 Background | Jul 2014 → Jan 2016 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT02369965 Comparator | Feb 2014 → Apr 2018 | AIDS | Frontier Biotechnologies Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01905059 Comparator | Feb 2014 → Apr 2016 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT01848743 Comparator | Apr 2013 → Apr 2016 | chronic hepatitis B virus infection | Kaohsiung Veterans General Hospital. | Unknown | No outcome recorded |
| Phase 3 | NCT02670772 Background | Jul 2012 → Dec 2014 | AIDS | Willem Daniel Francois Venter | Completed | No outcome recorded |
| Phase 3 | NCT01605084 Background | Jun 2012 → Aug 2014 | HIV infectious disease | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 3 | NCT01580202 Comparator | Apr 2012 → Jun 2017 | cancer, hepatitis B virus infection | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01516970 Background | Nov 2011 → Aug 2013 | HIV infectious disease | Janssen-Cilag GmbH | Completed | No outcome recorded |
| Phase 3 | NCT01363011 Background | May 2011 → Jan 2013 | AIDS | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01237444 Comparator | Dec 2010 → May 2012 | HIV infectious disease | Pedro Cahn | Completed | No outcome recorded |
| Phase 3 | NCT01252940 Background | Nov 2010 → Jan 2012 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00936195 Comparator | Jan 2010 → Jan 2013 | HIV infectious disease, pregnancy disorder | French National Agency for Research on AIDS and Viral Hepatitis | Withdrawn | No outcome recorded |
| Phase 3 | NCT00993031 Background | Dec 2009 → Jul 2013 | HIV infectious disease, malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT00640263 Comparator | Dec 2009 → May 2013 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 3 | NCT00978068 Comparator | Sep 2009 → Jan 2013 | HIV infectious disease, malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT00727597 Background | Jul 2008 → Aug 2010 | HIV infectious disease | Georgetown University | Completed | No outcome recorded |
| Phase 3 | NCT00708162 Background | Jul 2008 → Dec 2010 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00410202 Comparator | Mar 2008 → Jan 2011 | chronic hepatitis B virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00427297 Background | Sep 2007 → May 2009 | HIV infectious disease | University of Washington | Terminated | No outcome recorded |
| Phase 3 | NCT01002898 Background | Apr 2007 → Feb 2011 | HIV infectious disease | Bamrasnaradura Infectious Diseases Institute | Completed | No outcome recorded |
| Phase 3 | NCT00440947 Background | Mar 2007 → Jul 2010 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT00234091 Comparator | Apr 2006 → Sep 2011 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00316719 Comparator | Jan 2006 → Jan 2008 | chronic hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00398996 Comparator | Jun 2005 → Jul 2010 | HIV infectious disease, pulmonary tuberculosis | Centre for the AIDS Programme of Research in South Africa | Completed | No outcome recorded |
| Phase 3 | NCT00098293 Background | Nov 2004 → Apr 2007 | — | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT00086359 Background | Jul 2004 → Sep 2007 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00095121 Background | Jun 2004 → May 2006 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00085943 Background | May 2004 → ? | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00318123 Background | Apr 2004 → Apr 2007 | HIV infectious disease | Germans Trias i Pujol Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00164736 Comparator | Mar 2004 → Jan 2010 | HIV infectious disease | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT00076336 Comparator | Dec 2003 → Dec 2009 | chronic hepatitis B virus infection, cirrhosis of liver | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00234923 Comparator | Aug 2003 → Feb 2007 | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00405925 Comparator | Mar 2003 → Aug 2009 | HIV infectious disease | Rijnstate Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00650637 Background | Jan → Aug 2003 | diarrheal disease | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00135382 Background | Jun 2002 → Oct 2005 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00017719 Background | May 2002 → Mar 2006 | HIV infectious disease, pregnancy disorder | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00013897 Background | Feb 2001 → Apr 2003 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00116298 Background | Jan 2001 → Jan 2005 | AIDS | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00009061 Background | Nov 2000 → ? | HIV infectious disease | Glaxo Wellcome | Unknown | No outcome recorded |
| Phase 3 | NCT00008554 Background | Nov 2000 → ? | HIV infectious disease | Glaxo Wellcome | Unknown | No outcome recorded |
| Phase 3 | NCT00005918 Background | Jun 2000 → Apr 2002 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00158821 Background | Mar 2000 → Dec 2001 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02181933 Comparator | Apr 1999 → Jan 2001 | HIV infectious disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00004583 Background | Mar 1999 → ? | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00966160 Comparator | Jan 1999 → Dec 2008 | AIDS | University of Cologne | Completed | No outcome recorded |
| Phase 3 | NCT00002371 Background | Jun 1996 → Dec 1997 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00004981 Background | — | HIV infectious disease | Glaxo Wellcome | Unknown | No outcome recorded |
| Phase 3 | NCT00000903 Background | ? → Jul 2001 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00002368 Background | — | HIV infectious disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00000841 Background | ? → Jun 1997 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00002199 Background | — | HIV infectious disease | Glaxo Wellcome | Completed | No outcome recorded |
| Phase 3 | NCT00002409 Background | — | HIV infectious disease | Glaxo Wellcome | Completed | No outcome recorded |
| Phase 3 | NCT00002378 Background | — | HIV infectious disease | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00005002 Background | — | HIV infectious disease | Agouron Pharmaceuticals | Unknown | No outcome recorded |
| Phase 3 | NCT00002389 Background | — | HIV infectious disease | Glaxo Wellcome | Completed | No outcome recorded |
| Phase 3 | NCT00002391 Background | — | HIV infectious disease | Glaxo Wellcome | Completed | No outcome recorded |
| Phase 3 | NCT00002195 Background | — | HIV infectious disease | Glaxo Wellcome | Completed | No outcome recorded |
| Phase 480 trials | ||||||
| Phase 4 | NCT07673965 Background | Aug 2026 → Aug 2027 expected | HIV infectious disease | University of Witwatersrand, South Africa | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07631897 Background | Jun 2026 → Jun 2028 expected | HIV infectious disease, tuberculosis | Shanghai Public Health Clinical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07138144 Comparator | Jul 2025 → Feb 2026 overdue | HIV infectious disease | José Antonio Mata Marín | Recruiting | No outcome recorded |
| Phase 4 | NCT07678268 Comparator | Jul 2025 → Jul 2026 overdue | HIV infectious disease | Mexican Social Security Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT06158126 Comparator | Apr 2024 → Dec 2026 expected | pregnancy disorder | University of North Carolina, Chapel Hill | Recruiting | No outcome recorded |
| Phase 4 | NCT05630638 Comparator | Oct 2023 → Jul 2028 expected | HIV infectious disease | University of Liverpool | Recruiting | No outcome recorded |
| Phase 4 | NCT05393193 Background | Jul 2022 → Mar 2026 overdue | HIV infectious disease | Harvard School of Public Health (HSPH) | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04296695 Comparator | Jul 2021 → Dec 2022 | HIV infectious disease | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04903847 Background | Feb 2021 → Feb 2023 | HIV infectious disease, impaired renal function disease, lipodystrophy, obesity disorder +1 | Thomas Benfield | Unknown | No outcome recorded |
| Phase 4 | NCT04904406 Background | Oct 2020 → Dec 2023 | HIV infectious disease, cardiovascular disorder, lipodystrophy | Thomas Benfield | Completed | No outcome recorded |
| Phase 4 | NCT04553081 Comparator | May 2020 → Jun 2026 overdue | HIV infectious disease | University Hospital, Ghent | Recruiting | No outcome recorded |
| Phase 4 | NCT04054089 Comparator | Jan 2020 | HIV infectious disease | Cristina Mussini | Completed | No outcome recorded |
| Phase 4 | NCT03916328 Comparator | Dec 2019 → Mar 2024 | bone resorption disease | MU-JHU CARE | Unknown | No outcome recorded |
| Phase 4 | NCT04076423 Comparator | Oct 2019 → Jun 2023 | HIV infectious disease | Fundacion SEIMC-GESIDA | Completed | No outcome recorded |
| Phase 4 | NCT07014189 Comparator | Apr 2019 → Jan 2023 | HIV infectious disease | Cantonal Hospital of St. Gallen | Completed | No outcome recorded |
| Phase 4 | NCT03685500 Comparator | Dec 2018 → Jun 2020 | HIV infectious disease | Fundacion SEIMC-GESIDA | Completed | No outcome recorded |
| Phase 4 | NCT03205566 Comparator | Sep 2017 → Sep 2018 | HIV infectious disease | Guy's and St Thomas' NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT03067285 Comparator | Sep 2017 → Apr 2019 | HIV infectious disease | Fundacion SEIMC-GESIDA | Completed | No outcome recorded |
| Phase 4 | NCT01818258 Comparator | Oct 2015 → Apr 2017 | HIV infectious disease, protein-energy malnutrition | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | Completed | No outcome recorded |
| Phase 4 | NCT02431975 Background | Aug 2015 → Apr 2020 | HIV infectious disease | Columbia University | Completed | No outcome recorded |
| Phase 4 | NCT02470650 Comparator | Jun 2015 → Jul 2017 | poisoning | Juan A. Arnaiz | Withdrawn | No outcome recorded |
| Phase 4 | NCT02482272 Comparator | May 2015 → Jan 2017 | chronic hepatitis B virus infection | Asan Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02057796 Background | Sep 2014 → Apr 2018 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 4 | NCT02894554 Comparator | Jul → Oct 2014 | — | National Taiwan University Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT02159599 Comparator | Jul 2014 → Apr 2016 | HIV infectious disease | Fundacion SEIMC-GESIDA | Completed | No outcome recorded |
| Phase 4 | NCT01829802 Comparator | May 2014 → Oct 2017 | HIV infectious disease | Pedro Cahn | Unknown | No outcome recorded |
| Phase 4 | NCT01618305 Background | Sep 2013 → Dec 2018 | HIV infectious disease | Westat | Completed | No outcome recorded |
| Phase 4 | NCT01641367 Background | Feb 2013 → Nov 2016 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 4 | NCT01694017 Comparator | Nov 2012 → Aug 2014 | HIV infectious disease | Tufts University | Completed | No outcome recorded |
| Phase 4 | NCT01732367 Comparator | Nov 2012 → Mar 2016 | chronic hepatitis B virus infection | Keimyung University Dongsan Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01491295 Comparator | Sep 2012 → Dec 2019 | chronic hepatitis B virus infection | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 4 | NCT01597934 Comparator | Aug 2012 → May 2014 | chronic hepatitis B virus infection | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT01637259 Comparator | Jun 2012 → Dec 2015 | HIV infectious disease, proteinuria | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT01595633 Background | Mar 2012 → Feb 2014 | chronic hepatitis B virus infection | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT02337127 Comparator | Jun 2011 → May 2015 | chronic hepatitis B virus infection | Kaohsiung Medical University Chung-Ho Memorial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01192035 Comparator | May 2011 → Sep 2014 | — | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT01804387 Comparator | May 2011 → Dec 2013 | chronic hepatitis B virus infection | Korea University | Unknown | No outcome recorded |
| Phase 4 | NCT01338025 Comparator | Mar 2011 → May 2013 | HIV infectious disease | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | Terminated | No outcome recorded |
| Phase 4 | NCT01340950 Comparator | Jul 2010 → Jul 2014 | HIV infectious disease, central nervous system disorder, dementia | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT01088009 Comparator | Mar 2010 → Feb 2013 | chronic hepatitis B virus infection | Nanfang Hospital, Southern Medical University | Completed | No outcome recorded |
| Phase 4 | NCT00986778 Comparator | Dec 2009 → Dec 2012 | chronic hepatitis B virus infection | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 4 | NCT01023217 Comparator | Nov 2009 → Jul 2012 | chronic hepatitis B virus infection | Asan Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00823550 Comparator | Jan 2009 → Jul 2014 | chronic hepatitis B virus infection | Yonsei University | Unknown | No outcome recorded |
| Phase 4 | NCT00798460 Comparator | Dec 2008 → Jun 2010 | chronic hepatitis B virus infection | Inje University | Terminated | No outcome recorded |
| Phase 4 | NCT00865007 Comparator | Dec 2008 → Jun 2012 | HIV infectious disease, lipodystrophy | Fundacion SEIMC-GESIDA | Completed | No outcome recorded |
| Phase 4 | NCT00772902 Comparator | Oct 2008 → Sep 2009 | — | Gilead Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00724711 Comparator | Jul 2008 → Mar 2011 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00627055 Comparator | May 2008 → Nov 2010 | HIV infectious disease | The HIV Netherlands Australia Thailand Research Collaboration | Completed | No outcome recorded |
| Phase 4 | NCT00617643 Background | May 2008 → Jun 2009 | HIV infectious disease, tuberculosis | Makerere University | Completed | No outcome recorded |
| Phase 4 | NCT00662545 Comparator | Apr 2008 → Feb 2010 | HIV infectious disease, hepatitis B virus infection | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT00625339 Comparator | Feb 2008 → Nov 2010 | chronic hepatitis B virus infection | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT00625560 Comparator | Feb 2008 → Nov 2009 | chronic hepatitis B virus infection | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT00637663 Comparator | Feb 2008 → Nov 2010 | chronic hepatitis B virus infection | Pusan National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00544128 Comparator | Oct 2007 → Feb 2012 | HIV infectious disease | International Medical Center of Japan | Completed | No outcome recorded |
| Phase 4 | NCT02028676 Comparator | Mar 2007 → Mar 2012 | HIV infectious disease | Medical Research Council | Completed | No outcome recorded |
| Phase 4 | NCT00393484 Comparator | Feb 2007 → Jan 2009 | chronic hepatitis B virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT00960622 Comparator | Aug 2006 → Jul 2009 | HIV infectious disease | St. Luke's-Roosevelt Hospital Center | Completed | No outcome recorded |
| Phase 4 | NCT00324649 Comparator | May 2006 → Mar 2008 | — | Gilead Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00246610 Background | Mar 2006 → Nov 2007 | HIV infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00335270 Background | Mar 2006 → Dec 2007 | HIV infectious disease | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT00192634 Comparator | Dec 2005 → Aug 2008 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT02598063 Background | Oct 2005 → Apr 2009 | chronic hepatitis B virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00141284 Background | Oct 2005 → Dec 2006 | HIV infectious disease, hepatitis C virus infection | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT01386970 Comparator | May 2005 → Jul 2008 | HIV infectious disease | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT00979706 Comparator | Mar 2005 → Nov 2014 | HIV infectious disease | Juan A. Arnaiz | Completed | No outcome recorded |
| Phase 4 | NCT00344760 Background | Jan 2005 → Mar 2007 | HIV infectious disease | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 4 | NCT00162643 Background | Dec 2004 → Dec 2007 | AIDS | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Unknown | No outcome recorded |
| Phase 4 | NCT00084253 Comparator | Jun 2004 → Aug 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 4 | NCT00256828 Background | Jun 2004 → Nov 2006 | HIV infectious disease | Clinical Trial Agency of HIV Study Group | Completed | No outcome recorded |
| Phase 4 | NCT00127972 Background | Feb 2004 → Apr 2007 | HIV infectious disease | International Antiviral Therapy Evaluation Center | Completed | No outcome recorded |
| Phase 4 | NCT00192595 Comparator | Jan 2004 → Jan 2007 | HIV infectious disease, hepatitis B virus infection | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT00342355 Comparator | Jan 2004 → Mar 2008 | HIV infectious disease | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 4 | NCT00230477 Comparator | Apr 2003 → Aug 2007 | hepatitis B virus infection | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT02300623 Background | Mar 2000 → Apr 2013 | HIV infectious disease | Juan A. Arnaiz | Completed | No outcome recorded |
| Phase 4 | NCT00005000 Background | Dec 1999 → ? | HIV infectious disease | Agouron Pharmaceuticals | Unknown | No outcome recorded |
| Phase 4 | NCT00005106 Background | Sep 1999 → ? | HIV infectious disease | Glaxo Wellcome | Completed | No outcome recorded |
| Phase 4 | NCT00710216 Comparator | — | chronic hepatitis B virus infection | University of Ulm | Withdrawn | No outcome recorded |
| Phase 4 | NCT00385957 Background | — | HIV infectious disease | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 4 | NCT02202473 Comparator | ? → Feb 2014 | chronic hepatitis B virus infection | Southeast University, China | Completed | No outcome recorded |
| Phase 4 | NCT00005017 Background | — | HIV infectious disease | Glaxo Wellcome | Unknown | No outcome recorded |
| Phase not applicable24 trials | ||||||
| — | NCT06609941 Background | Jun 2024 → Jan 2025 overdue | asthma | Foundation University Islamabad | Recruiting | No outcome recorded |
| — | NCT07618507 Comparator | Apr 2022 → Mar 2024 | HIV infectious disease | Federal University of São Paulo | Completed | No outcome recorded |
| — | NCT03405194 Comparator | May 2018 → May 2020 | HIV infectious disease | Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic | Withdrawn | No outcome recorded |
| — | NCT02827643 Comparator | Jun 2016 → Mar 2017 | bone disorder | Mahidol University | Unknown | No outcome recorded |
| — | NCT03076359 Background | Jun 2015 → May 2019 | HIV infectious disease | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT01844310 Comparator | May 2013 → Dec 2015 | AIDS | Peking Union Medical College | Unknown | No outcome recorded |
| — | NCT01583439 Background | Sep 2012 → Feb 2013 | HIV infectious disease | Harvard School of Public Health (HSPH) | Terminated | No outcome recorded |
| — | NCT02002286 Background | Aug 2011 → May 2013 | HIV infectious disease | LI Taisheng | Completed | No outcome recorded |
| — | NCT01387022 Background | Jun 2011 → Nov 2014 | — | Centre for the AIDS Programme of Research in South Africa | Completed | No outcome recorded |
| — | NCT01344174 Background | May → Aug 2011 | hepatitis B virus infection, liver failure | Third Military Medical University | Unknown | No outcome recorded |
| — | NCT01318096 Background | Mar 2011 → Jul 2012 | HIV infectious disease | Yunnan AIDS Care Center | Unknown | No outcome recorded |
| — | NCT01139203 Comparator | Aug 2009 → Dec 2012 | hepatitis B virus infection | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| — | NCT00428116 Comparator | Sep 2007 → Jul 2013 | HIV infectious disease | University of Washington | Terminated | No outcome recorded |
| — | NCT01013272 Comparator | Jun 2007 → Jul 2010 | chronic hepatitis B virus infection | The University of Hong Kong | Completed | No outcome recorded |
| — | NCT00255840 Comparator | Jul 2006 → Jan 2009 | HIV infectious disease | CIPRA SA | Completed | No outcome recorded |
| — | NCT00346567 Comparator | Jun 2006 → Oct 2010 | HIV infectious disease | Rigshospitalet, Denmark | Completed | No outcome recorded |
| — | NCT00087945 Background | Jul → Dec 2004 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00006441 Background | Feb 2003 → Oct 2008 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00002430 Background | — | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| — | NCT00051090 Background | — | HIV infectious disease, hepatitis B virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| — | NCT00034086 Background | ? → Jun 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00000875 Background | ? → Apr 2003 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| — | NCT00000923 Background | ? → Aug 2004 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00002369 Background | — | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT01776996 Background | — | HIV infectious disease | ViiV Healthcare | No longer available | No outcome recorded |
Press releases naming this drug 21 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-09-05 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV viatris.com ↗ |
| 2018-03-05 | Gilead Sciences | Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lamivudine gilead.com ↗ |
| 2011-05-26 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval of Generic Combivir Tablets: Launch Expected in Fourth Quarter 2011 tevapharm.com ↗ |
| 2007-10-29 | Gilead Sciences | Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients gilead.com ↗ |
| 2007-07-23 | Gilead Sciences | 144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney gilead.com ↗ |
| 2006-12-15 | Gilead Sciences | 96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome gilead.com ↗ |
| 2006-08-14 | Gilead Sciences | 96-Week Data from Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination with Sustiva(R) Presented at XVI International AIDS Conference gilead.com ↗ |
| 2006-01-18 | Gilead Sciences | Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of Combination HIV Therapy Published in New England Journal of Medicine gilead.com ↗ |
| 2005-11-17 | Gilead Sciences | Preliminary 24-Week Data Evaluating the Impact of Switching from Twice-Daily Combivir(R) to Once-Daily Truvada(R) in Patients with HIV Presented at 10th European AIDS Conference gilead.com ↗ |
| 2005-02-03 | Gilead Sciences | Gilead Announces Preliminary 48-Week Data From Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Sustiva in Patients With HIV gilead.com ↗ |
| 2004-10-31 | Gilead Sciences | Interim 24-Week Data from Study 934 Comparing a Regimen of Viread and Emtriva Versus Combivir, Both in Combination with Efavirenz, in Patients with HIV Presented at 44th ICAAC gilead.com ↗ |
| 2004-08-26 | Gilead Sciences | Gilead Announces Preliminary 24-Week Data from Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Efavirenz In Patients With HIV gilead.com ↗ |
| 2003-10-28 | Gilead Sciences | Gilead Announces 144-Week Data of Hepsera in Patients Co-Infected With HIV And Lamivudine-Resistant HBV gilead.com ↗ |
| 2003-08-11 | Gilead Sciences | Gilead Initiates Study 934, a 48-Week Clinical Trial Evaluating Viread and Emtriva versus Combivir gilead.com ↗ |
| 2002-11-04 | Gilead Sciences | New Data Demonstrate Antiviral Activity of Gilead's Hepsera in Patients with Lamivudine-Resistant Chronic Hepatitis B gilead.com ↗ |
| 2002-04-19 | Gilead Sciences | Data From Study of Gilead's Adefovir Dipivoxil in Hepatitis B Patients With Lamivudine-Resistant Virus Presented At International Medical Meeting gilead.com ↗ |
| 2002-04-18 | Gilead Sciences | 92-Week Data From Clinical Study of Gilead's Adefovir Dipivoxil in Patients Co-Infected With HIV and Lamivudine-Resistant HBV Presented At International Medical Meeting gilead.com ↗ |
| 2001-11-13 | Gilead Sciences | Gilead Announces Data from Studies of Adefovir Dipivoxil in Patients with Lamivudine-Resistant Chronic Hepatitis B Virus Infection gilead.com ↗ |
| 2001-11-09 | Gilead Sciences | Gilead Announces Primary Endpoint Met in Phase III Study of Adefovir Dipivoxil 10 mg in Patients with Lamivudine-Resistant Chronic Hepatitis B Infection gilead.com ↗ |
| 2000-04-11 | Gilead Sciences | Gilead Presents Preliminary Clinical Data Describing Activity of Adefovir Dipivoxil Against Lamivudine-Resistant Hepatitis B Virus gilead.com ↗ |
| 1999-04-09 | Gilead Sciences | Gilead Presents Preliminary Clinical Data Demonstrating Activity of Adefovir Dipivoxil Against Lamivudine-Resistant Hepatitis B Virus gilead.com ↗ |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 639 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lamivudine | “Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195 ↗558“This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed...” NCT00085943 ↗ “Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose...” NCT00955968 ↗ “Both HIV and HBV can be treated with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC), so we evaluated the safety and efficacy of combination antiretroviral therapy...” PMID 26831232 ↗ Feb 2016 “Objective:To evaluate the effectiveness, safety, and tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) compared with...” NCT07075146 ↗ “A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine,...” NCT00214435 ↗ “Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC,...” NCT01363011 ↗ “Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir...” NCT05729568 ↗ “Second generation integrase inhibitor 1) Bictegravir 50 mg/ alafenamide tenofovir 25 mg/ emtricitabine 200 mg (BIC/TAF/FTC); 2) Dolutegravir 50 mg/ abacavir 600 mg/ lamivudine...” NCT06602622 ↗ “NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF,...” NCT01252940 ↗ “Patients will be on their existing nucleosid(t)e analogue therapy comprising lamivudine 100mg daily, adefovir 10mg daily, entecavir 0.5mg or 1.0mg daily or tenofovir 300mg...” NCT01928511 ↗ “Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the...” NCT00110305 ↗ “The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate p.o. q.d. or EPZICOM™/KIVEXA™, a tablet containing...” NCT02275780 ↗ “The three antiretroviral drugs have been chosen because they are the only ones that allow administration at higher doses without causing increased toxicity: dolutegravir 50...” NCT06640192 ↗ “These study will explore how fast NVP is eliminated from women after delivery and to see if given zidovudine/lamivudine (AZT/3TC) for 1 or 2 weeks after NVP discontinuation can...” NCT00872872 ↗ “For those subjects in South Africa and Argentina who were previously receiving Combivir along with maraviroc in Study A4001026, Combivir will be supplied as tablets containing...” NCT01776996 ↗ “The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and...” NCT00753324 ↗ “Our study aims to verify the safety and efficacy of a simplification of a dual therapy (Lamivudine plus Atazanavir with Ritonavir), confiding on the potency and high genetic...” NCT00885482 ↗ “Bictegravir 50 mg / tenofovir alafenamide 25 mg / emtricitabine 200 mg or dolutegravir 50 mg / lamivudine 300 mg / abacavir 600 mg, both combinations in a single tablet, will...” NCT07138144 ↗ “The second large phase III study has compared doravirine 100 mg once daily to efavirenz, a first generation NNRTI, with tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) in...” NCT05477407 ↗ “Eighty HIV infected patients failing first-line regimens with serum creatinine lower than 1.5 times the upper limit of normal received TDF+ lamivudine (3TC)+ LPV/r were...” PMID 25821963 ↗ Mar 2015 “adult FDC of abacavir/dolutegravir/lamivudine and adult FDC of dolutegravir/lamivudine with their respective pediatric FDC formulations, taken as dispersion immediately or...” PMID 34817414 ↗ Mar 2022 “Doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo®) 100 mg doravirine, 300 mg lamivudine,300 mg tenofovir disoproxil fumarate equivalent to 245 mg de tenofovir...” NCT04233372 ↗ “Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.” NCT02002286 ↗ “Triomune is manufactured by a generic drug company and consists of three drugs combined in a single pill given twice daily (stavudine 30mg plus lamivudine 150mg plus nevirapine 200mg).” NCT00617643 ↗ “The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir” NCT00820118 ↗ “The abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) 600 milligrams (mg)/50 mg/300 mg fixed-dose combination (FDC) tablet is currently approved in the United States (US) and Europe.” NCT02539576 ↗ “Efficacy and Safety of Tenofovir Disoproxil Fumarate Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy for ART-naive Chinese Patients With HIV-1 Infection” NCT01844297 ↗ “the dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) tablet is being made available to women who become pregnant while participating in study ING117172” NCT02075593 ↗ “Lamivudine (3TC) is a commonly used NRTI that is well tolerated and approved for young infants and children as a component in the first and second-line regimens in guidelines.” NCT01656122 ↗ “NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.” NCT01440569 ↗ “This study aims to investigate the pharmacokinetic interactions between the TDF and the nucleosides abacavir (ABV) and lamivudine (3TC) at plasma and intracellular level.” NCT00335192 ↗ “Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)” NCT00380770 ↗ “Darunavir/cobicistat 800/150 mg + lamivudine 300 mg This arm is the experimental one, with dual therapy, 2 drugs: darunavir/cobicistat 800/150 mg plus lamivudine 300 mg” NCT06907056 ↗ “Doravirine 100 mg (Pifeltro®) will be administered once daily in combination with co-formulated dolutegravir/lamivudine 50/300 mg (Dovato®) for a duration of 48 weeks.” NCT06037564 ↗ “currently either efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg or efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg” NCT02591420 ↗ “Stavudine 20mg twice daily for 96 weeks + Placebo 300mg once daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks” NCT02670772 ↗ “Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz” NCT02827643 ↗ “Fixed dose combination of Tenofovir 300 mg/Emtricitabine 200 mg or Tenofovir 300 mg/Lamivudine 300 mg plus Ritonavir Boosted Atazanavir 300/100mg given once a day” NCT01829802 ↗ “Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)” NCT01943799 ↗ “film-coated tablet contains abacavir sulphate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg dolutegravir, and 300 mg of lamivudine.” NCT02938520 ↗ “tenofovir disoproxil fumarate (TDF) once daily plus lamivudine (3TC) twice daily plus LPV/r 400/100 mg twice daily (TDF/3TC/LPV/r) at nine sites in Thailand.” PMID 23075703 ↗ Jul 2012 “300 mg of zidovudine (ZDV), 150 mg of lamivudine, and 200 mg nevirapine (NVP) was given twice daily from 34 weeks gestation until six months after delivery.” NCT00167674 ↗ “receive abacavir sulfate/lamivudine/zidovudine (ABC/3TC/ZDV) twice-daily or atazanavir (ATV) once-daily plus lamivudine/zidovudine (3TC/ZDV) twice-daily.” PMID 19358725 ↗ Apr 2009 “One hundred subjects in Russia will be treated with a combination of Combivir (zidovudine and lamivudine) and maraviroc as their first line HIV therapy.” NCT01275625 ↗ “Pharmacokinetic Study of Twice Daily vs Once Daily Lamivudine and Abacavir as Part of Combination Antiretroviral Therapy in Children With HIV Infection” NCT01982396 ↗ “Delstrigo (300 mg of tenofovir disoproxil fumarate equivalent to 245 mg of tenofovir disoproxil, 300 mg of lamivudine and 100 mg of doravirine” NCT05289986 ↗ “1 (lamivudine) or 2 (lamivudine + abacavir) nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications once daily” NCT00796263 ↗ “Triumeq, a combination of dolutegravir, abacavir and lamivudine is an anti-retroviral therapy indicated for people with HIV-1 infection.” NCT02868580 ↗ “fixed tenofovir disoproxil fumarate (300 mg once daily) plus either lamivudine (300 mg once daily) or emtricitabine (200 mg once daily).” PMID 38788744 ↗ May 2024 “Accepted NRTIs: abacavir sulfate (ABC), emtricitabine (FTC), emtricitabine/Tenofovir disoproxil fumarate (FTC/TDF), lamivudine (3TC)” NCT00039741 ↗ “Other approved antivirals (such as lamivudine, entecavir, or immunoglobulin antihepatitis B) administered per local practice” NCT02862548 ↗ “Immediate Bitherapy (BI) strategy Dolutegravir (DTG, Tivicay® 50 mg QD) plus lamivudine (3TC, 300 mg QD) between D0 and W96.” NCT04051970 ↗ “Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription.” NCT00772902 ↗ “Each capsule contains Lopinavir (40mg), Ritonavir (10mg), Abacavir (30mg) and Lamivudine (15mg) in granules formulation.” NCT03836833 ↗ “Dual therapy of 2 drugs co-formulated in 1 tablet: Dolutegravir 50 mg/ lamivudine 300 mg, it is the experimental group” NCT07031063 ↗ “Efavirenz EFV 200 mg (3 tablets/d) Lamivudine 3TC 300mg (2 tablets of 150mg/d) D4T generic 30mg or 40mg (2 tablets/d)” NCT00495326 ↗ “Dolutegravir 50mg oral with tenofovir disoproxil fumarate (245mg) and lamivudine (300mg) in a fixed dose combination” NCT05154747 ↗ “Once-daily dolutegravir 50 mg with tenofovir disoproxil fumarate 300 mg and lamivudine 300 mg was initiated on day 0” PMID 40349709 ↗ May 2025 “For intolerance to Truvada, Combivir (zidovudine 300mg/lamivudine 150mg)will be available to be taken as 1 PO BID.” NCT00949234 ↗ “Ritonavir-boosted lopinavir in soft gel formulation at 400/100 mg and lamivudine at 150 mg were given twice daily.” NCT01002898 ↗ “Lamivudine (Epivir®, 3TC) 10 mg/ml for oral solution administered twice daily at WHO weight band dose for 48 weeks” NCT01818258 ↗ “Children received a standard WHO-recommended regimen of open-label lamivudine, abacavir, plus NNRTI continuously.” NCT02028676 ↗ “Abacavir (ABC) 600 milligrams (mg)/Dolutegravir(DTG) 50 mg/Lamivudine (3TC) 300 mg fixed-dose combination (FDC)” NCT02105987 ↗ “Trizivir® is a combination of three antiretroviral agents: Abacavir, Lamivudine and Zidovudine in a tablet.” NCT00865475 ↗ “Dual therapy consisted of lopinavir 400 mg and ritonavir 100 mg plus lamivudine 150 mg, both twice daily.” PMID 24783988 ↗ Apr 2014 “This is a fixed-dose combined DTG/3TC pill each containing 50mg of dolutegravir and 300mg of lamivudine” NCT06444620 ↗ “patients who currently successfully use zidovudine (AZT) and lamivudine (3TC) as part of their regimen” NCT00389194 ↗ “100mg of doravirine (DOR), 300mg of lamivudine (3TC), and 300mg of tenofovir disoproxil fumarate (TDF)” NCT04665375 ↗ “continued lamivudine 100mg po daily and traditional supporting treatments will be given for 13 weeks.” NCT01344174 ↗ “received single once-daily dolutegravir-lamivudine fixed-dose combination tablet orally for 48 weeks” PMID 39988749 ↗ Jun 2025 “remain suppressed upon switching to dolutegravir/lamivudine (DTG/3TC) fixed dose combination (FDC).” NCT04021290 ↗ “zidovudine, lamivudine, nevirapine or zidovudine, lamivudine if their mother is infected with HIV-2” NCT03642704 ↗ “Plus Tenofovir Disoproxil Fumarate (TDF) and Lamivudine in a Fixed-Dose Combination Tablet (Combo)” NCT03595709 ↗ “oral lopinavir 400 mg and oral ritonavir 100 mg twice daily plus oral lamivudine 300 mg once daily” PMID 26062880 ↗ Jun 2015 “Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)” NCT03602690 ↗ “Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) or lamivudine (3TC) (FTC/TDF or TDF/3TC)” NCT06158126 ↗ “Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg)” NCT01595633 ↗ “2 NRTIs (lamivudine 150 mg "bis in die - twice a day" (BID) and either zidovudine 300 mg BID” NCT01192035 ↗ “300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily” NCT00270296 ↗ “The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens” NCT00152061 ↗ “Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg” NCT01597934 ↗ “once-daily combination of abacavir (ABC) + lamivudine (3TC) + EFV (referred to as EFV)” PMID 28434406 ↗ Apr 2017 “600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine, i.e. 1 tablet, once daily” NCT02556268 ↗ “lopinavir/ritonavir plus abacavir/lamivudine versus lopinavir/ritonavir monotherapy.” PMID 23386261 ↗ Feb 2013 “zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year” NCT01694017 ↗ “two-drug regimen of dolutegravir (DTG) 50 milligram (mg) + lamivudine (3TC) 300 mg” NCT03446573 ↗ “Switch to dual therapy with Dolutegravir (50 mg) + lamivudine (300 mg) once daily” NCT03447873 ↗ “Lamivudine - potent selective inhibitor of HIV-1 and HIV-2 replication in vitro.” NCT06676410 ↗ “nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine” NCT03256422 ↗ “Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life.” PMID 21666540 ↗ Sep 2011 “Nucleos(t)ide analogues includes adefovir, entecavir, lamivudine or tenofovir.” NCT01706575 ↗ “Lamivudine 100mg QD for 36 months (adjust dosage according to renal function)” NCT01491295 ↗ “to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs” NCT00300573 ↗ “Fixed dose combination of doravirine, lamivudine and tenofovir disoproxil” NCT05630638 ↗ “100 mg of doravirine (DOR), 300 mg of lamivudine (3TC), and 300 mg of TDF” NCT05457530 ↗ “HAART: The first line was Zidovudine(AZT)+Lamivudine(3TC)+Efavirenz(EFV)” NCT01344148 ↗ “In the arms with NRTIs, 86% of patients received zidovudine/lamivudine.” PMID 19363330 ↗ Apr 2009 “HIV therapy consisting of a nucleoside with lamivudine and efavirenz.” NCT01075152 ↗ “both in combination with zidovudine/lamivudine 300/150 mg twice daily” PMID 23782005 ↗ Jul 2013 “early switching to dolutegravir/lamivudine (DTG/3TC) in single-pill” NCT04979468 ↗ “A.antiviral drugs(Entecavir,Lamivudine,Adefovir dipivoxil,et al)” NCT01844063 ↗ “Oral Dolutegravir/Lamivudine Once-daily as a First-line Regimen” NCT05917509 ↗ “tenofovir disoproxil fumarate plus lamivudine or emtricitabine” NCT04183738 ↗ “dolutegravir/lamivudine (DTG/3TC) fixed dose combination (FDC)” NCT05911360 ↗ “Name of active ingredients:Abacavir/lamivudine/dolutegravir” NCT02509195 ↗ “Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated)” NCT00708162 ↗ “efavirenz 600 mg once daily plus tenofovir and lamivudine” PMID 24726095 ↗ Apr 2014 “lamivudine 150 mg plus zidovudine 300 mg BID dosed orally” NCT00246610 ↗ “Zidovudine 300mg and lamivudine 150mg BID for 6 months” NCT00490620 ↗ “Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine” NCT02246998 ↗ “remain on abacavir (600 mg) plus lamivudine (300 mg)” PMID 29475804 ↗ Feb 2018 “tenofovir in addition to emtricitabine or lamivudine” NCT00662545 ↗ “Dolutegravir 50mg /Lamivudine 300mg/ Tenofovir 300mg” NCT04734652 ↗ “Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC)” NCT00643968 ↗ “switch to dolutegravir/lamivudine (DTG/3TC, n = 89)” PMID 39226296 ↗ Feb 2025 “short-course zidovudine (AZT) and lamivudine (3TC)” PMID 19859531 ↗ Oct 2009 “dolutegravir (DTG)/abacavir (ABC)/lamivudine (3TC)” NCT06630299 ↗ “abacavir 600mg + lamivudine 300mg in one tablet QD” NCT00318123 ↗ “atazanavir 400mg + abacavir 600mg/lamivudine 300mg” NCT01102972 ↗ “1. Dolutégravir 50mg / Lamivudine 300mg per day” NCT04867083 ↗ “containing tenofovir, zidovudine and lamivudine” NCT00356616 ↗ “AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)” NCT00428116 ↗ “Epzicom (abacavir 600 mg / lamivudine 300 mg)” NCT00727597 ↗ “Azidothimidine + lamivudine + nevirapine Or” NCT01174914 ↗ “TRIUMEQ (Dolutegravir/Abacavir/Lamivudine)” NCT04827134 ↗ “Lamivudine will be used with all children.” NCT00978068 ↗ “associated to lamivudine (3TC - 300mg)” NCT06338826 ↗ “And lamivudine is added for 3 months.” NCT00860626 ↗ “3. Lamivudine 300 mg once a day” NCT02588820 ↗ “tenofovir/lamivudine/efavirenz” NCT02750059 ↗ “dolutegravir/lamivudine” NCT04295460 ↗ “lamivudine 300 mg daily” NCT01367236 ↗ “lamivudine/zidovudine” NCT01516970 ↗ “Lamivudine (Epivir® )” NCT03491553 ↗ “Lamivudine (300 mg)” NCT01605084 ↗ “Lamivudine 300mg od” NCT02245022 ↗ “lamivudine \[3TC\]” NCT04012931 ↗ “lamivudine (3TC)” NCT00006617 ↗ “lamivudine (3TC)” NCT03631732 ↗ “lamivudine (3TC)” NCT00336778 ↗ “Lamivudine (3TC）” NCT02231281 ↗ “lamivudine (3TC)” NCT06337032 ↗ “lamivudine (3TC)” NCT02016924 ↗ “Lamivudine (LAM)” NCT00316719 ↗ “Lamivudine (3TC)” NCT01338025 ↗ “Drug: Lamivudine” NCT01936233 ↗ “lamivudine,” NCT02157311 ↗ “Lamivudine” NCT02231281 ↗ “Lamivudine” NCT02300623 ↗ “lamivudine” NCT01210287 ↗ “lamivudine” NCT01637259 ↗ |
| Known as | 3-thiacytidine | “Lamivudine (also known as 3-thiacytidine: 3TC) is an antiviral medication given as a pill once a day for twelve months.” NCT00001457 ↗ |
| Known as | 3TC | “First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV...” NCT03076359 ↗227“The purpose of this study is to compare long-term safety and tolerability of stavudine (d4T) extended release (ER) versus conventional (immediate release [IR]) formulations,...” NCT00116298 ↗ “Multi-center Study to Evaluate Virological Efficacy, Safety Tolerability, Drug Exposure and Patients' Reported Outcomes Over 48 Weeks Following Randomization to 2-drug Therapy...” NCT05735535 ↗ “Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose...” NCT00955968 ↗ “Daily Antiretroviral Therapy (DART-II): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial To Evaluate the Efficacy and Safety fo Stavudine Extended Release...” NCT00116116 ↗ “BACKGROUND: New regimens may provide better tolerability, convenience, and safety for nonoccupational human immunodeficiency virus (HIV) postexposure prophylaxis (PEP). For...” PMID 37539061 ↗ Jul 2023 “An International, Double Blind, Randomized, Phase III Study to Evaluate the Tolerance, Safety, and Effectiveness of Viramune (Nevirapine) in Preventing Clinical AIDS...” NCT00002368 ↗ “Both HIV and HBV can be treated with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC), so we evaluated the safety and efficacy of combination antiretroviral therapy...” PMID 26831232 ↗ Feb 2016 “Objective:To evaluate the effectiveness, safety, and tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) compared with...” NCT07075146 ↗ “Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC,...” NCT01363011 ↗ “The investigators propose to evaluate the safety of combination therapy comprising the three nucleoside analog reverse-transcriptase inhibitors (NRTIs) zidovudine (AZT),...” NCT02363452 ↗ “To compare the efficacy of lamivudine (3TC) and zidovudine (AZT) in combination versus the better of didanosine (ddI) monotherapy or ddI/AZT combination, in symptomatic HIV-1...” NCT00001066 ↗ “The purpose of this study is to see if it is safe to give saquinavir-SGC (SQV) combined with low-dose ritonavir (RTV) plus zidovudine (ZDV) and lamivudine (3TC) to HIV-positive...” NCT00000920 ↗ “A Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety and Efficacy of the Combination of 1592U89/Zidovudine (ZDV)/Lamivudine (3TC) Versus the Combination of...” NCT00002391 ↗ “In Pediatric AIDS Clinical Trials Group 377, antiretroviral therapy-experienced children were randomized to 4 treatment arms that included different combinations of stavudine,...” PMID 11372025 ↗ May 2001 “BACKGROUND: Study 903 is a phase 3 trial with a completed 144-week, double-blind phase comparing tenofovir DF (TDF) with stavudine (d4T), in combination with lamivudine (3TC)...” PMID 18042503 ↗ Nov 2007 “The ANRS 12174 trial assessed the efficacy and tolerance of lopinavir (LPV)-ritonavir (LPV/r) prophylaxis versus those of lamivudine (3TC) prophylaxis administered to breastfed...” PMID 27895016 ↗ Jan 2017 “Investigational Product Tenofovir disoproxil fumarate / lamivudine / dolutegravir Dosage Formulation 300 mg / 300 mg / 50 mg fixed dose combination tablet Route of...” NCT06485154 ↗ “Tenofovir disoproxil fumarate + emtricitabine/ lamivudine Dosage Formulation: 300 mg / 200 mg (300mg) fixed dose combination tablet Route of Administration: Oral Dosing...” NCT07006246 ↗ “The efficacy and tolerance of switching from zidovudine (ZDV) and lamivudine (3TC) in clinically stable HIV-infected children with incomplete viral suppression to stavudine...” PMID 11840078 ↗ Feb 2002 “The purpose of this study is to compare the safety and effectiveness of saquinavir SGC plus stavudine (d4T) plus lamivudine (3TC) with that of saquinavir SGC plus nelfinavir...” NCT00002397 ↗ “These study will explore how fast NVP is eliminated from women after delivery and to see if given zidovudine/lamivudine (AZT/3TC) for 1 or 2 weeks after NVP discontinuation can...” NCT00872872 ↗ “The aim of this study was to investigate the effect on fasting lipid parameters of switching to tenofovir disoproxil fumarate (TDF) plus emtricitabine (FTC) from abacavir (ABC)...” PMID 22910324 ↗ Aug 2012 “A Randomized, Double-Blind, Phase III Study of Indinavir Sulfate With Open-Label Zidovudine (AZT) and Lamivudine (3TC) in Subjects With HIV Infection With CD4 Cell Counts <=...” NCT00000841 ↗ “the presence of low level nucleoside reverse-transcriptase inhibitor-resistant human immunodeficiency virus in subjects receiving failing first-line regimens consisting of...” PMID 19032103 ↗ Jan 2009 “A Pilot Study to Evaluate the Immunologic Consequences of a Highly Active Antiretroviral Therapy Regimen (HAART) Consisting of Ritonavir (ABT-538), Zidovudine (AZT), and...” NCT00001075 ↗ “Arm I options are enteric-coated didanosine (ddI-EC) plus lamivudine (3TC), ddI-EC plus zidovudine (ZDV), ZDV plus 3TC (or Combivir), stavudine (d4T) plus 3TC, or ddI-EC plus...” NCT00014937 ↗ “Double reverse transcriptase inhibitor (RTI) therapy consisting of any two therapy combinations of: didanosine (ddI), lamivudine (3TC), stavudine (d4T) or zidovudine (ZDV),...” NCT00002376 ↗ “The purpose of this study is to compare the safety and effectiveness of taking lamivudine (3TC) plus zidovudine (ZDV) plus a protease inhibitor (PI) with taking the 3TC/ZDV...” NCT00002203 ↗ “The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and...” NCT00753324 ↗ “The purpose of this study is to see if it is safe and effective to give ritonavir (RTV) plus lamivudine (3TC) plus zidovudine (ZDV) to HIV-infected pregnant women during...” NCT00000888 ↗ “Volunteers were randomized 1:1 into two sequences containing three treatment groups (DOR, lamivudine [3TC], and TDF alone; estradiol, spironolactone, and placebo; and...” PMID 38421210 ↗ Mar 2024 “Participants were centrally randomised to receive once-daily oral GSK'254 100 (N = 22), 150 (N = 20), or 200 mg (N = 22) or lamivudine (3TC) 300 mg (double-blinded dose) (N =...” PMID 41357331 ↗ Oct 2025 “This study aims to evaluate the safety and effectiveness of the tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) + efavirenz (EFV) regimen in antiretroviral therapy...” NCT01844297 ↗ “The combination of didanosine, lamivudine, and efavirenz (ddI/3TC/EFV) for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection has been...” PMID 18781872 ↗ Oct 2008 “The extent and manner by which HIV nucleoside reverse transcriptase inhibitors contribute to insulin resistance is unclear. We evaluated the effect of zidovudine/lamivudine...” PMID 19898246 ↗ Feb 2010 “Treatment-naive adults were randomized to nevirapine (NVP) or ritonavir-boosted lopinavir (LPV/r) regimens each in combination with tenofovir (TDF)/emtricitabine (FTC) or...” PMID 25028911 ↗ May 2014 “An Open-Label, Non-Comparative Study of Saquinavir-SGC in Combination With Zidovudine (AZT) and Lamivudine (3TC) in the Treatment of HIV-1 Infected Patients With No Previous...” NCT00002367 ↗ “The purpose of this study is to see whether taking indinavir (IDV) plus ritonavir (RTV) plus stavudine (d4T) plus lamivudine (3TC) 2 times each day is safe and can lower the...” NCT00002241 ↗ “A Phase I Trial of the Safety, Tolerance, and Pharmacokinetics of Oral Nelfinavir (Viracept) Co-Administered With Zidovudine (ZDV) and Lamivudine (3TC) in HIV Infected Pregnant...” NCT00000887 ↗ “Lamivudine (3TC) is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection...” NCT02634073 ↗ “The second large phase III study has compared doravirine 100 mg once daily to efavirenz, a first generation NNRTI, with tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) in...” NCT05477407 ↗ “Initiation of once daily ddI (400 / 250mg), 3TC (300mg) and EFV (600mg)during the intensive phase of TB therapy or during the continuation phase of TB therapy or once TB...” NCT00398996 ↗ “A single tablet FDC containing doravirine 100 mg, lamivudine (3TC) 300 mg and tenofovir disoproxil fumarate (TDF) 300 mg administered orally, once daily for 12 weeks during the...” NCT02652260 ↗ “The purpose of this study is to see if it is safe and effective to give an anti-HIV drug combination of indinavir (IDV) plus stavudine (d4T) plus lamivudine (3TC) to...” NCT00000901 ↗ “bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) or dolutegravir/lamivudine/abacavir (DTG/3TC/ABC), are associated with metabolic, renal, and cardiovascular adverse effects” NCT07138144 ↗ “The nucleoside analogue combinations provided on this study are as follows: zidovudine (ZDV) plus didanosine (ddI), ZDV plus lamivudine (3TC), stavudine (d4T) plus 3TC, or d4T plus ddI.” NCT00000923 ↗ “The abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) 600 milligrams (mg)/50 mg/300 mg fixed-dose combination (FDC) tablet is currently approved in the United States (US) and Europe.” NCT02539576 ↗ “Patients receive specific combinations of 3 or 4 of the following 6 drugs: didanosine (ddI), stavudine (d4T) efavirenz (EFV), nelfinavir (NFV), lamivudine (3TC), or zidovudine (ZDV).” NCT00000919 ↗ “the dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) tablet is being made available to women who become pregnant while participating in study ING117172” NCT02075593 ↗ “Dolutegravir (DTG) and lamivudine (3TC) are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.” NCT02738931 ↗ “The 7 drugs that will be given in this study are stavudine (d4T), didanosine (ddI), lamivudine (3TC), nelfinavir (NFV), ritonavir (RTV), saquinavir (SQV), and nevirapine (NVP).” NCT00001108 ↗ “Lamivudine (3TC) is a commonly used NRTI that is well tolerated and approved for young infants and children as a component in the first and second-line regimens in guidelines.” NCT01656122 ↗ “NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.” NCT01440569 ↗ “The purpose of this study is to compare two anti-HIV drugs, FTC and lamivudine (3TC), when given with either stavudine (d4T) or zidovudine (ZDV) and one other anti-HIV drug.” NCT00002416 ↗ “This study will see how safe and effective against HIV the drugs L-756423 plus indinavir (IDV) are compared to just IDV when taken with stavudine (d4T) and lamivudine (3TC).” NCT00002424 ↗ “This is a pilot study investigating the efficacy of Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks” NCT04429152 ↗ “A phase 2 randomized, controlled trial of a regimen containing tenofovir (TDF)/lamivudine (3TC) and a regimen containing 3TC in HIV/HBV-coinfected pregnant women in China.” PMID 27658693 ↗ Sep 2016 “A sensitive LC/MS/MS assay for determining zidovudine (ZDV) and lamivudine (3TC) in human plasma was validated to support antiretroviral pharmacology research programs.” PMID 21465499 ↗ Apr 2011 “Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir DF/emtricitabine (TDF/FTC) are widely used nucleoside reverse transcriptase inhibitors for initial HIV-1 treatment.” PMID 19542866 ↗ Jul 2009 “Patients receiving combination antiretroviral therapy with indinavir (IDV), zidovudine (ZDV)(or d4T) and lamivudine (3TC) show viral suppression for two years or more.” NCT00000916 ↗ “Antiretroviral therapy, administered orally non nonnucleoside reverse transcriptase inhibitor (NNRTIs), examples: ABC/ DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)” NCT07115368 ↗ “tenofovir disoproxil fumarate (TDF) once daily plus lamivudine (3TC) twice daily plus LPV/r 400/100 mg twice daily (TDF/3TC/LPV/r) at nine sites in Thailand.” PMID 23075703 ↗ Jul 2012 “receive abacavir sulfate/lamivudine/zidovudine (ABC/3TC/ZDV) twice-daily or atazanavir (ATV) once-daily plus lamivudine/zidovudine (3TC/ZDV) twice-daily.” PMID 19358725 ↗ Apr 2009 “Arm 1 (integrated arm) participants will receive didanosine (ddI), efavirenz (EFV), and lamivudine (3TC) once daily concurrent with standard TB therapy.” NCT00091936 ↗ “A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants” NCT00000878 ↗ “A Feasibility Study of Lamivudine/Zidovudine (3TC/ZDV) Plus Efavirenz (EFV) as Initial Therapy of HIV-1 Infected Patients in a Rural Area of China” NCT00100594 ↗ “Randomised, controlled, superiority trial of virologically suppressed PLWH on dolutegravir, abacavir and lamivudine (DTG/ABC/3TC) for ≥6 months.” PMID 37604629 ↗ Aug 2023 “3TC may be added as a third NRTI to a dual-NRTI background regimen in subjects with chronic HBV infection and evidence of HIV resistance to 3TC” NCT02227238 ↗ “a fixed-dose combination oral tablet of dolutegravir/lamivudine (DTG/3TC) and cabotegravir plus rilpivirine long-acting agents (CAB + RPV LA).” NCT05917509 ↗ “The two combinations are abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) and zidovudine/lamivudine (ZDV/3TC) plus lopinavir/ritonavir (LPV/RTV).” NCT00086359 ↗ “Fixed dose combination abacavir/lamivudine/zidovudine (ABC/3TC/ZDV) among HIV-1 and tuberculosis (TB)-coinfected patients was evaluated” PMID 20001518 ↗ Dec 2009 “In Step 1 of this 2-step protocol, all patients receive a HAART regimen of nelfinavir (NFV) plus stavudine (d4T) plus lamivudine (3TC).” NCT00000899 ↗ “Accepted NRTIs: abacavir sulfate (ABC), emtricitabine (FTC), emtricitabine/Tenofovir disoproxil fumarate (FTC/TDF), lamivudine (3TC)” NCT00039741 ↗ “All patients will receive open label induction therapy with zidovudine (ZDV), lamivudine (3TC) and indinavir (IDV) for 6 months.” NCT00001084 ↗ “The combination of ZDV/3TC (Combivir®) and Lopinavir/ritonavir (LPV/r) (Kaletra® or Aluvia®) is chosen as a reference regimen” NCT00936195 ↗ “Immediate Bitherapy (BI) strategy Dolutegravir (DTG, Tivicay® 50 mg QD) plus lamivudine (3TC, 300 mg QD) between D0 and W96.” NCT04051970 ↗ “Participants received dolutegravir/lamivudine (DTG/3TC) (50/300 mg) Fixed Dose Combination (FDC) tablets orally once daily.” NCT03682848 ↗ “Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF) and Efavirenz(EFV)/Lamivudine/Tenofovir Regimens” NCT07631897 ↗ “Group 1 receives GW433908 plus abacavir (ABC) plus lamivudine (3TC); Group 2 receives nelfinavir (NFV) plus ABC plus 3TC.” NCT00008554 ↗ “Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks” NCT04433780 ↗ “Lamivudine (also known as 3-thiacytidine: 3TC) is an antiviral medication given as a pill once a day for twelve months.” NCT00001457 ↗ “Antiretroviral therapy, administered orally Non-NNRTIs, examples: ABC/ DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)” NCT07001319 ↗ “Efavirenz EFV 200 mg (3 tablets/d) Lamivudine 3TC 300mg (2 tablets of 150mg/d) D4T generic 30mg or 40mg (2 tablets/d)” NCT00495326 ↗ “tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) and either efavirenz (EFV) or lopinavir/ritonavir (LPV/r)” NCT00100581 ↗ “Lamivudine (Epivir®, 3TC) 10 mg/ml for oral solution administered twice daily at WHO weight band dose for 48 weeks” NCT01818258 ↗ “The study-specified NRTIs will be abacavir (ABC) plus lamivudine (3TC) or didanosine (ddI) plus stavudine (d4T).” NCT00000922 ↗ “Abacavir (ABC) 600 milligrams (mg)/Dolutegravir(DTG) 50 mg/Lamivudine (3TC) 300 mg fixed-dose combination (FDC)” NCT02105987 ↗ “Arm A - 141W94, plus Zidovudine (ZDV) and Lamivudine (3TC) or Arm B - 141W94, plus ZDV placebo and 3TC placebo.” NCT00001085 ↗ “GW433908/ritonavir (RTV) to viral response to nelfinavir (NFV) when used with abacavir (ABC)/lamivudine (3TC)” NCT00009061 ↗ “Stavudine (d4T) + Lamivudine (3TC) + Zidovudine placebo or Zidovudine (ZDV) + Lamivudine + Stavudine placebo” NCT00002371 ↗ “Zidovudine (ZDV) and lamivudine (3TC) metabolism to triphosphates (TP) is necessary for antiviral activity.” PMID 17664328 ↗ Jul 2007 “3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg TPW 3 wks switch to 150 mg OD 4 wks);” NCT00651066 ↗ “The drugs to be used in combination with DLV are zidovudine (ZDV), indinavir (IDV), and lamivudine (3TC).” NCT00002401 ↗ “Stavudine (d4T) + Didanosine (ddI) + Lamivudine (3TC) or d4T + ddI + Indinavir or d4T + ddI + Nevirapine.” NCT00002407 ↗ “Patients with HIV-1 and Kaposi sarcoma (KS) received generic nevirapine, stavudine, and lamivudine (3TC);” PMID 15633090 ↗ Dec 2004 “This is a fixed-dose combined DTG/3TC pill each containing 50mg of dolutegravir and 300mg of lamivudine” NCT06444620 ↗ “100mg of doravirine (DOR), 300mg of lamivudine (3TC), and 300mg of tenofovir disoproxil fumarate (TDF)” NCT04665375 ↗ “patients who currently successfully use zidovudine (AZT) and lamivudine (3TC) as part of their regimen” NCT00389194 ↗ “remain suppressed upon switching to dolutegravir/lamivudine (DTG/3TC) fixed dose combination (FDC).” NCT04021290 ↗ “Subjects will switch to dolutegravir (DTG) plus lamivudine (3TC) or fixed dose combination DTG/3TC.” NCT05493969 ↗ “TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg)” NCT02150993 ↗ “In this approach, drug resistant mutants would be selected by administration of Lamivudine (3TC).” NCT00001080 ↗ “Tenofovir disoproxil fumarate (TDF) 300 mg / Lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)” NCT02273765 ↗ “fixed dose combination (FDC) of Dolutegravir (DTG) plus Lamivudine (3TC) as a first line regimen” NCT03945981 ↗ “Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) or lamivudine (3TC) (FTC/TDF or TDF/3TC)” NCT06158126 ↗ “Lamivudine (3TC) has been approved by regulatory authorities for the treatment of HIV infection” NCT00985647 ↗ “d4T 20 mg twice daily and TDF, taken in combination with lamivudine (3TC) and efavirenz (EFV).” PMID 30640204 ↗ Feb 2019 “indinavir (IDV) and ritonavir (RTV) in combination with stavudine (d4T) and lamivudine (3TC)” NCT00002451 ↗ “The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens” NCT00152061 ↗ “efficacy, safety, and pharmacokinetics of lamivudine (3TC) combined with zidovudine” NCT00000838 ↗ “two-drug regimen of dolutegravir (DTG) 50 milligram (mg) + lamivudine (3TC) 300 mg” NCT03446573 ↗ “A Randomized Lamivudine (3TC)/Dideoxycytidine (ddC) Double-Blind Multicenter Trial” NCT00002436 ↗ “abacavir 600 mg + lamivudine (3TC) 300 mg in 1 tablet + efavirenz 600 mg 1/24h” NCT00314626 ↗ “Combivir (Zidovudine (AZT) plus lamivudine (3TC)) and nevirapine twice a day;” NCT00143689 ↗ “for example Tenofovir disoproxil fumarate (TDF)+ lamivudine (3TC) or TDF+FTC” NCT01318096 ↗ “Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)” NCT03549689 ↗ “D4T/3TC/EFV(600mg)+INH/Rifabutin(450 mg OD 4 wks switch to 600 mg OD 4 wks)” NCT00640887 ↗ “Abacavir (ABC) and lamivudine (3TC) administered twice daily were compared” PMID 16280696 ↗ Dec 2005 “Non-NNRTIs, examples: ABC/DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)” NCT05585307 ↗ “100 mg of doravirine (DOR), 300 mg of lamivudine (3TC), and 300 mg of TDF” NCT05457530 ↗ “HAART: The first line was Zidovudine(AZT)+Lamivudine(3TC)+Efavirenz(EFV)” NCT01344148 ↗ “Dolutegravir (DTG) plus lamivudine (3TC) is a dual regimen combination” NCT04880785 ↗ “Patients also receive open-label efavirenz (EFV) and lamivudine (3TC).” NCT00005918 ↗ “Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets” NCT03760458 ↗ “Doravirine (DOR)/Lamivudine (3TC)/Tenofovir Disproxyl Fumarate (TDF)” NCT06034938 ↗ “Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)” NCT00440947 ↗ “in Combination With Lamivudine (3TC) and Efavirenz (EFV) Once Daily” NCT00116415 ↗ “early switching to dolutegravir/lamivudine (DTG/3TC) in single-pill” NCT04979468 ↗ “Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers” NCT06519357 ↗ “lopinavir/ritonavir plus lamivudine (3TC) versus standard therapy” NCT01237444 ↗ “abacavir (ABC)/lamivudine (3TC)/zidovudine (ZDV)/efavirenz (EFV)” NCT00013520 ↗ “abacavir sulfate (ABC), lamivudine (3TC), and zidovudine (AZT)” NCT00084149 ↗ “dolutegravir/lamivudine (DTG/3TC) fixed dose combination (FDC)” NCT05911360 ↗ “Lipovirtide 10mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）” NCT06061536 ↗ “stable regimen with DTG/abacavir (ABC)/lamivudine (3TC)” PMID 30601976 ↗ Oct 2019 “whether it is beneficial to add lamivudine (3TC) to AZT” NCT00000831 ↗ “zidovudine (ZDV), stavudine (D4T) and lamivudine (3TC)” NCT00001095 ↗ “indinavir plus lamivudine (3TC) plus zidovudine (ZDV)” NCT00000944 ↗ “DMP 266 plus zidovudine (ZDV) plus lamivudine (3TC)” NCT00002410 ↗ “Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC)” NCT00643968 ↗ “switch to dolutegravir/lamivudine (DTG/3TC, n = 89)” PMID 39226296 ↗ Feb 2025 “Gammora® SC + Tenofovir/3TC + darunavir+ritonavir” NCT06799650 ↗ “lamivudine (3TC)/abacavir (ABC)/stavudine (d4T)” NCT00005017 ↗ “RAL 400 mg BID + TDF 300 mg QD + 3TC 150 mg BID” NCT01837277 ↗ “Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC)” NCT01910402 ↗ “Combivir (zidovudine [AZT] / lamivudine [3TC])” NCT00192621 ↗ “AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)” NCT00427297 ↗ “3TC (Lamivudine; GR109714X) Open-Label Program” NCT00002108 ↗ “AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)” NCT00428116 ↗ “Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)” NCT02632474 ↗ “abacavir (ABC) 600mg + lamivudine (3TC) 300mg” NCT00192634 ↗ “lamivudine (3TC)/zidovudine (ZDV)/1592U89 arm” NCT00002199 ↗ “Zidovudine Plus Lamivudine (3TC) Versus d4T” NCT00001067 ↗ “Open Label, Switch to Triumeq (ABC/DTG/3TC)” NCT03275701 ↗ “Dolutegravir (DTG) and lamivudine (3TC)” NCT04337450 ↗ “Lamivudine (3TC; GR109714X) Monotherapy” NCT00002320 ↗ “associated to lamivudine (3TC - 300mg)” NCT06338826 ↗ “Lamivudine (3TC) and Zidovudine (ZDV)” NCT00002389 ↗ “lamivudine (3TC) given with stavudine” NCT00002442 ↗ “Dolutegravir (DTG)/ Lamivudine (3TC)” NCT07393659 ↗ “Dolutegravir / Lamivudine (DTG/3TC)” NCT07202546 ↗ “Dolutegravir + Lamivudine (DTG/3TC)” NCT04022967 ↗ “Neviparine (NVP)/ Lamivudine (3TC)” NCT07014189 ↗ “abacavir (ABC)/lamivudine (3TC)” NCT00724711 ↗ “abacavir (ABC)-lamivudine (3TC)” PMID 21606537 ↗ Jun 2011 “lamivudine 300 mg (DTG/ABC/3TC)” NCT06602622 ↗ “Lamivudine (3TC) 150 mg tablets” NCT02116660 ↗ “lamivudine (3TC) (300 mg daily)” PMID 41644158 ↗ Feb 2026 “abacavir/lamivudine (ABC/3TC)” NCT02246998 ↗ “lamivudine (3TC) plus d4T” NCT00001087 ↗ “lamivudine (3TC; 300 mg)” PMID 33336698 ↗ Jul 2021 “Lamivudine (3TC)300mg qd” NCT00618176 ↗ “Epivir (Lamivudine; 3TC)” NCT00002234 ↗ “Lamivudine (3TC) 300 mg” NCT06676410 ↗ “Drug: Lamivudine (3TC)” NCT02181933 ↗ “Combivir® (ZDV+3TC)” NCT02256774 ↗ “lamivudine \[3TC\]” NCT04012931 ↗ “lamivudine ( 3TC )” NCT00002155 ↗ “lamivudine (3TC)” NCT00122538 ↗ “Lamivudine (3TC)” NCT00000865 ↗ “lamivudine (3TC)” NCT00005000 ↗ “lamivudine (3TC)” NCT00002386 ↗ “lamivudine (3TC)” NCT00312091 ↗ “lamivudine (3TC)” NCT00002208 ↗ “Lamivudine (3TC）” NCT02231281 ↗ “lamivudine (3TC)” NCT00002245 ↗ “Lamivudine (3TC)” NCT02831673 ↗ “lamivudine (3TC)” NCT00000891 ↗ “Lamivudine (3TC)” NCT03539224 ↗ “Lamivudine (3TC)” NCT00300573 ↗ “Lamivudine (3TC)” NCT00158405 ↗ “lamivudine (3TC)” NCT02016924 ↗ “lamivudine (3TC)” NCT00336778 ↗ “lamivudine (3TC)” NCT00006617 ↗ “Lamivudine (3TC)” NCT02831764 ↗ “lamivudine (3TC)” NCT00006443 ↗ “Lamivudine (3TC)” NCT00000882 ↗ “lamivudine (3TC)” NCT06337032 ↗ “Lamivudine (3TC)” NCT02249130 ↗ “Lamivudine (3TC)” NCT04731103 ↗ “lamivudine (3TC)” NCT00004736 ↗ “lamivudine (3TC)” NCT03631732 ↗ “DTG + 3TC” NCT04076423 ↗ |
| Known as | 3TC-ZDV | “Lamivudine-Zidovudine (3TC-ZDV)” NCT01061151 ↗ |
| Known as | 3TC: lamivudine: Epivir | “3TC: lamivudine: Epivir” NCT02028676 ↗ |
| Known as | COMBIVIR | “the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated)” NCT00708162 ↗7“Combivir (Nucleoside analogue - reverse transcriptase inhibitor)” NCT06609941 ↗ |
| Known as | Epivir | “A Phase I/II, Open Label Study to Evaluate the Ability of Combination Therapy With ABT-378/Ritonavir (Kaletra), Lamivudine (Epivir), Efavirenz (Sustiva)and Tenofovir DF to...” NCT00038220 ↗10“100 patients will be randomized to receive Zerit (Stavudine) + Epivir (Lamivudine) + Crixivan (Indinavir) and 100 patients will be randomized to receive Retrovir (Zidovudine) +...” NCT00002369 ↗ “combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day.” NCT02527096 ↗ “Lamivudine (Epivir, GSK), Atazanavir (Reyataz, BMS), Ritonavir (Norvir, Abbott)” NCT01599364 ↗ “150 mg lamivudine (Epivir tablets, GlaxoSmithKline)” NCT00966160 ↗ “Epivir (Lamivudine; 3TC)” NCT00002234 ↗ “Lamivudine (Epivir® )” NCT03491553 ↗ “Lamiduvine (Epivir)” NCT00885482 ↗ “Epivir (Lamivudine)” NCT00002168 ↗ |
| Known as | GR109714X | “3TC (Lamivudine; GR109714X) Open-Label Program” NCT00002108 ↗1“Lamivudine (3TC; GR109714X) Monotherapy” NCT00002320 ↗ |
| Known as | LAM | “BACKGROUND: The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable...” PMID 29329305 ↗ Jan 20185“The objective of this prospective randomized clinical trial was to compare the strategy of HBV monotherapy with lamivudine (LAM) or tenofovir disoproxil fumarate (TDF) versus...” PMID 18697216 ↗ Oct 2008 “Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections.” PMID 32460460 ↗ May 2020 “Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated)” NCT00708162 ↗ “Lamivudine (LAM)” NCT01095835 ↗ “Lamivudine (LAM)” NCT00316719 ↗ |
| Known as | Lamivudina | “Resistance Profile to Antiretroviral Medications in Individuals Living With HIV Who Failed a First-Line Regimen With Tenofovir / Lamivudina and Dolutegravir in Brasil” NCT07618507 ↗ |
| Known as | Lamivudine (3TC) | “Lamivudine (3TC)” NCT01338025 ↗ |
| Known as | Lamivudine (Zeffix) | “Lamivudine (Zeffix)” NCT01546116 ↗ |
| Known as | lamivudine 100 mg tablets (GlaxoSmithKline); | “lamivudine 100 mg tablets (GlaxoSmithKline);” NCT01894269 ↗ |
| Known as | Lamivudine-Zidovudine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01061151 ↗ |
| Known as | LVD | “we conducted a randomized controlled trial in which CHB patients with spontaneous SAE were randomized to receive lamivudine (LVD) or entecavir (ETV)” PMID 28671553 ↗ 2018 |
| Action | Inhibit | “nucleoside reverse transcriptase inhibitors” NCT00000882 ↗ |
| Modality | Other / unclassified | “HIV nucleoside reverse transcriptase inhibitors (NRTI)” PMID 16103764 ↗ Sep 2005 |
| Route | Oral | “Oral 3TC.” NCT00000878 ↗ |